Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.

Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA.

Blood. 1991 Dec 1;78(11):2814-22.

2.

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al.

Blood. 1995 Apr 15;85(8):2025-37.

3.

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.

Ribera JM, Ortega JJ, Oriol A, Fontanillas M, Hernández-Rivas JM, Brunet S, García-Conde J, Maldonado J, Zuazu J, Gardella S, Besalduch J, León P, Macià J, Domingo-Albós A, Feliu E, San Miguel JF.

Haematologica. 1998 Mar;83(3):222-30.

4.

Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

Schrappe M, Aricò M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G.

Blood. 1998 Oct 15;92(8):2730-41.

5.

Improved results of treatment of adult acute lymphoblastic leukemia.

Linker CA, Levitt LJ, O'Donnell M, Ries CA, Link MP, Forman SJ, Farbstein MJ.

Blood. 1987 Apr;69(4):1242-8.

6.

Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.

Rivera GK, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM, Pui CH.

Blood. 1996 Aug 1;88(3):831-7.

7.

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.

Cancer. 2004 Dec 15;101(12):2788-801.

8.

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.

Kobayashi T, Tobinai K, Shimoyama M, Mikuni C, Konda S, Kozuru M, Araki K, Sai T, Fukuhara S, Matsumoto M, Aoki I, Deura K, Oyama A, Hotta T, Abe T, Toki H, Nagai M, Fukuda H, Niimi M, Yamaguchi N, Tajima K, Shirakawa S.

Jpn J Clin Oncol. 1999 Jul;29(7):340-8.

PMID:
10470659
9.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology.

Haematologica. 2002 Feb;87(2):154-66.

10.

[Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].

Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, Rosas-Arzate G, Armengolt-Jiménez A, Aguayo A, López-Karpovitch X, Crespo-Solís E.

Rev Invest Clin. 2008 Nov-Dec;60(6):459-69. Spanish. Erratum in: Rev Invest Clin. 2009 Jan-Feb;61(1):90.

PMID:
19378832
11.

Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy.

Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, et al.

Blood. 1989 Jan;73(1):57-63.

12.
13.

Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E; PETHEMA Group.

Eur J Haematol. 2007 Feb;78(2):102-10. Epub 2006 Nov 6.

PMID:
17087744
14.

Dose-intensive therapy for adult acute lymphoblastic leukemia.

Finiewicz KJ, Larson RA.

Semin Oncol. 1999 Feb;26(1):6-20. Review.

PMID:
10073558
15.

Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).

Tanimoto M, Miyawaki S, Ino T, Kyo T, Sakamaki H, Naoe T, Hiraoka A, Asou N, Ohshima T, Tsubaki K, Kuriyama K, Ueda T, Minamil S, Okabe K, Saito H, Murakami H, Hirano M, Dohy H, Onozawa Y, Suzuki H, Ohno R.

Int J Hematol. 1998 Dec;68(4):421-9.

PMID:
9885441
16.

Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.

Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, Egurbide I, Hernández Rivas JM, Rivas C, Alcalá A, Besalduch J, Maciá J, Gardella S, Carnero M, Lite JM, Casanova F, Martinez M, Fontanillas M, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatías Malignas.

Haematologica. 2001 Jun;86(6):586-95.

17.

[Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].

Doubek M, Mayer J, Korístek Z, Protivánková M, Brychtová Y, Oborilová A, Král Z, Klabusay M, Tomíska M, Buchtová I, Vorlícek J.

Cas Lek Cesk. 2002 Mar 1;141(4):122-6. Czech.

PMID:
12046256
18.

Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.

Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R.

Haematologica. 2007 Mar;92(3):342-8.

19.

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.

Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F; GIMEMA Group.

Blood. 2002 Feb 1;99(3):863-71.

20.

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.

Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ; PETHEMA Group, Spain.

Haematologica. 2005 Oct;90(10):1346-56.

Supplemental Content

Support Center